Mainz Biomed (NASDAQ:MYNZ – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($3.60) per share and revenue of $0.25 million for the quarter.
Mainz Biomed Stock Performance
NASDAQ MYNZ opened at $2.98 on Monday. Mainz Biomed has a 52-week low of $2.65 and a 52-week high of $45.20. The company has a fifty day moving average of $5.26 and a 200-day moving average of $7.02. The company has a market capitalization of $5.96 million, a P/E ratio of -0.05 and a beta of 0.53.
Analyst Upgrades and Downgrades
Separately, Maxim Group initiated coverage on Mainz Biomed in a report on Friday, February 14th. They issued a “buy” rating and a $14.00 price objective for the company.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Recommended Stories
- Five stocks we like better than Mainz Biomed
- What Are Some of the Best Large-Cap Stocks to Buy?
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- 3 Tickers Leading a Meme Stock Revival
- Disney 2025 Shareholders: Major Updates for Investors
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Advance Auto Parts Stock: A Classic Rebound Play in the Making
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
